PRME (Prime Medicine) GF Value : $0.00 (As of Mar. 30, 2025)

View and export this data going back to 2022. Start your Free Trial

What is Prime Medicine GF Value?

As of today (2025-03-30), Prime Medicine's share price is $1.99. Prime Medicine's GF Value is $0.00. Therefore, Prime Medicine's Price-to-GF-Value for today is . Based on the relationship between the current stock price and the GF Value, GuruFocus believes Prime Medicine is Not Valued.

The GF Value represents the intrinsic value of a stock, determined using GuruFocus' proprietary methodology. The GF Value Line on our stock Summary page provides an estimate of the stock’s fair-trading value.

To calculate this value, GuruFocus follows these steps:

We analyze historical correlations between the stock price and key business performance metrics, such as revenue, earnings, cash flow, and book value.
We identify the metrics that have the strongest historical correlation with the stock price and determine the historical multiples at which the stock has traded relative to these metrics.
Using these historical multiples as a reference, we estimate the stock's fair value while accounting for future business growth. Adjustments may be made based on the company’s past returns and growth trends.

GuruFocus believes that the GF Value Line represents the fair value at which a stock should trade. Stock prices typically fluctuate around this line. If a stock’s price is significantly above the GF Value Line, it is considered overvalued, and its future returns are likely to be lower. Conversely, if the stock price is significantly below the GF Value Line, its future returns are likely to be higher.

Please note that "Possible Value Trap, Think Twice" applies to companies that appear significantly undervalued but are either experiencing a long-term business decline or facing financial distress.

Prime Medicine (NAS:PRME) GF Value Explanation

Based on the relationship between the current stock price and the GF Value, GuruFocus provides the following 6 ratings:

Posssible Evaluations	All-in-One Screener Examples (2)
Possible Value Trap, Think Twice (1)	Predictable Companies that possibly be Value Traps
Significantly Overvalued	Predictable Companies which are Significantly Overvalued
Modestly Overvalued	Predictable Companies which are Modestly Overvalued
Fairly Valued	Predictable High Quality Companies which are Fairly Valued
Modestly Undervalued (3)	Predictable High Quality Companies which are Modestly Undervalued
Significantly Undervalued (3)	Predictable High Quality Companies which are Significantly Undervalued

(1) "Possible Value Trap, Think Twice" applies to companies that appear significantly undervalued but are either experiencing a long-term business decline or facing financial distress.

(2) These are some simple examples. You can access our GF Valuation filter under All-in-One Screener’s Fundamental tab, and Price-to-GF-Value filter under Valuation Ratio tab and set your own criteria.

(3) A sufficient margin of safety exists only when the stock is undervalued.

Prime Medicine's Price-to-GF-Value for today is calculated as

Price-to-GF-Value	=	Share Price	/	GF Value
	=	1.99	/	0.00
	=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Prime Medicine GF Value Related Terms

Thank you for viewing the detailed overview of Prime Medicine's GF Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Prime Medicine Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Prime Medicine Inc (NAS:PRME) » Definitions » GF Value

Comparable Companies

Traded in Other Exchanges

N/A

Address

60 First Street, Cambridge, MA, USA, 02141

Website

https://www.primemedicine.com

Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.

Executives

Robert Nelsen	director, 10 percent owner	8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Arch Venture Partners X, Llc	10 percent owner	8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Gv 2019 Gp, L.l.c.	10 percent owner	1600 AMPHITHEATRE PKWY, MOUNTAIN VIEW CA 94043
Jeffrey D Marrazzo	director	3737 MARKET STREET, SUITE 1300, PHILADELPHIA PA 19104
2019, L.p. Gv	10 percent owner	1600 AMPHITHEATRE PKWY, MOUNTAIN VIEW CA 94043
Alphabet Inc.	10 percent owner	1600 AMPHITHEATRE PARKWAY, MOUNTAIN VIEW CA 94043
Gv 2019 Gp, L.p.	10 percent owner	1600 AMPHITHEATRE PKWY, MOUNTAIN VIEW CA 94043
2021, L.p. Gv	10 percent owner	1600 AMPHITHEATRE PARKWAY, MOUNTAIN VIEW CA 94043
Gv 2021 Gp, L.l.c.	10 percent owner	1600 AMPHITHEATRE PARKWAY, MOUNTAIN VIEW CA 94043
Gv 2021 Gp, L.p.	10 percent owner	1600 AMPHITHEATRE PARKWAY, MOUNTAIN VIEW CA 94043
Thomas Cahill	director	PRIME MEDICINE, INC., 21 ERIE ST., CAMBRIDGE MA 02139
Keith Crandell	10 percent owner	8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Carman Alenson	officer: See Remarks	88 SIDNEY STREET, CAMBRIDGE MA 02139
Meredith Goldwasser	officer: SVP, Strategy & Corporate Ops.	PRIME MEDICINE, INC., 21 ERIE ST., CAMBRIDGE MA 02139
Jeremy Duffield	officer: Chief Scientific Officer	PRIME MEDICINE, INC., 21 ERIE ST., CAMBRIDGE MA 02139